Connect with us

Business

The New Marijuana Research Bill Is Another Sign That Federal Prohibition Is Ending

Published

on

More research will give HHS and DOJ more data that will support the fact that marijuana’s Schedule I status is absolutely ridiculous.

On Friday, December 2, 2022, the White House announced that President Biden signed House Resolution 8454, into law:

H.R. 8454, the “Medical Marijuana and Cannabidiol Research Expansion Act,” which establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development.


According to Kyle Jaeger of Marijuana Moment, this is a significant and historic moment in cannabis reform:

President Joe Biden has officially signed a marijuana research bill into law, making history by enacting the first piece of standalone federal cannabis reform legislation in U.S. history.

HR 8454 is not just historic because it’s the first standalone cannabis legislation in US history, it is also likely going to play a major role in ending federal prohibition.

In October, Biden requested that the Department of Health and Human Services (HHS) and the Department of Justice (DOJ) evaluate marijuana’s Schedule I status.The CSA establishes a process for determining the scheduling of substances and relies on research to support any movement across the schedules or to remove a substance from the CSA all together. For years, the feds have used the same outdated studies showing that marijuana is dangerous and without medical benefit. This has created a Catch-22 as described by cannabis policy expert John Hudak in a 2016 interview with NPR:

There is this cannabis Catch-22 and it is, as a Schedule 1 drug, it is very difficult to do research on the plant. There are only certain researchers who will get the certification and licensure necessary to handle the drug. Then, of course, you need the funding to study it. You need approval from university institutional review boards, and the burdens that exist to do the type of research on a Schedule 1 drug are tremendous. But that research is what will inform the medical community as to its medical use, and so what you need and what you can do are entirely prevented by this federal government policy.

HR 8485 could allow researchers to finally break this Catch-22 loop. More research will give HHS and DOJ more data that will support the fact that marijuana’s Schedule I status is absolutely ridiculous. That could very well lead Biden’s administration to remove marijuana from Schedule I and hopefully from the CSA all together.

cannabis research
Photo by Nastasic/Getty Images

How HR 8485 Works

The CSA governs drugs at the federal level, including marijuana. Any controlled substance must be handled in compliance with the CSA. Marijuana is a Schedule I substance, which is the most restrictive category for any drug in the US. Schedule I substances are nearly impossible to research because they are deemed to have no medical use and too dangerous for use even with a doctor.

The registration requirements for any person or entity hoping to research scheduled substances are contained in 21 USC 823(f). The new law amends 21 USC 823(f) by requiring the Attorney General to register practitioners to conduct research on marijuana and its derivatives, extracts, preparations, and compounds, if the applicants research protocol has been reviewed and approved by the Department of HHS, the National Institute of Health, and otherwise in compliance with federal regulations on research protocols. The applicant must also demonstrate how it will control marijuana to prevent diversion or otherwise unlawful use.

HR 8454 also outlines what an application for marijuana research will entail. It also establishes security requirements and requires that the Attorney General and HHS consult to determine if there is an adequate supply of marijuana, including specific strains for research, and prepare a report to Congress on the matter.

HR 8485 also allows institutes of higher education, practitioners, or manufacturers to manufacture, distribute, dispense, or possess marijuana or cannabidiol if the purpose is for medical research for drug development so long as that person or entity is registered with the Food and Drug Administration (FDA).

HR 8485 also mandates that HHS, the National Institute of Health, and other federal agencies all report to Congress on the CBD, marijuana (including delta-9 THC), and the barriers associated with researching marijuana and CBD in states that have legalized their use. HHS and company will also be required to make recommendations on whether state-legal cannabis can be researched by federal agencies.

Source: https://thefreshtoast.com/marijuana-legislation/the-new-marijuana-research-bill-is-another-sign-that-federal-prohibition-is-ending/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News